Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 12/22/2018 |
| Start Date: | September 28, 2017 |
| End Date: | September 28, 2018 |
A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease
This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study
in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of ITI-214.
in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of ITI-214.
Major Inclusion Criteria:
- Clinical diagnosis of idiopathic Parkinson's disease (PD)
- Severity of PD assessed by Hoehn and Yahr Staging score of 1 to 3
- Maintenance on stable PD therapy
Major Exclusion Criteria:
- Clinical signs of dementia
- Suicidal ideation or behavior
- Considered medically inappropriate for study participation
We found this trial at
2
sites
Click here to add this to my saved trials
Atlanta Center for Medical Research Welcome to the Atlanta Center for Medical Research, a leader...
Click here to add this to my saved trials